Type 2 Diabetes Integrated Polygenic Risk Score™
What is our iPRS™ for Type 2 Diabetes (T2D) test?
The MyOme Integrated Polygenic Risk Score™ (iPRS™) for Type 2 Diabetes combines whole-genome insights with clinical factors—such as age, sex, BMI, blood pressure, cholesterol, and lifestyle—to provide a person’s absolute 10-year risk of developing T2D. This integrated approach is more accurate than clinical factors alone, enabling earlier and more personalized prevention strategies. The test has been validated across multiple ancestries to ensure broad applicability.
Comprehensive T2D Risk Assessment with iPRS
Hidden Risk Detection
Up to approximately 70% of T2D risk is due to heritable factors, many of which can be detected as genetic markers by the iPRS test1
Reliable Risk Stratification
A high iPRS score predicted a greater than 2.5 times increase in the 10-year incidence of T2D compared to the low iPRS group2
From Risk to Prevention
In people at increased risk for T2D, greater than 55% reduced their incidence of T2D by adopting lifestyle interventions3
Clinical risk factor analysis includes:
- Current Age
- Sex
- Waist circumference
- Smoking status
- Systolic blood pressure
- Family history of T2D
- Fasting glucose
- HDL-C
- Triglycerides
Who is this test for?
The T2D iPRS test is intended for individuals aged 35–70 who do not already have Type 2 Diabetes or use insulin/antidiabetic medications. By providing a clear and personalized risk estimate, the test helps individuals and their providers make informed decisions about screening, prevention, and lifestyle changes—empowering them to reduce their risk or delay the onset of disease.
Test Code
PR41027
(T2D iPRS, Proactive Health Plus)
PR42023
(T2D iPRS, Proactive Health)
Turn Around Times
From samples received, most results are delivered in 5 to 6 weeks*.
If you've already had MyOme testing performed, follow-up testing or re-requisitions are typically completed in under 2 weeks, often within just a few days.
Acceptable Sample Types
- Blood
- Buccal
- Saliva
Order a T2D iPRS test
We make it easy to order a T2D iPRS test to get insights for personalized care decisions.
This test can be ordered as part of the MyOme Proactive Health or MyOme Proactive Health Plus offerings depending on your needs. In addition, it can be ordered by itself.
Proactive Health Plus leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions.
Proactive Health uses blended genome-exome—offering a cost-effective option for preventative health decisions.
Interpreting T2D iPRS Results
Implications for T2D and Risk Reduction
Clinical guidelines recommend using established risk factors—such as family history, body mass index, age, and laboratory markers like fasting glucose or HbA1c—to guide type 2 diabetes prevention and management.
At higher levels of estimated risk, early interventions such as lifestyle modification, weight management, and in some cases preventive medications (e.g., metformin) are recommended to reduce risk of progression to diabetes.
Additional testing, such as glucose tolerance or continuous monitoring, may also help refine risk. T2D iPRS provides an added layer of genetic insight, supporting a more personalized risk management plan tailored to each individual.
Important considerations
The T2D iPRS test is a screening tool, not a diagnostic test. It does not detect high-risk monogenic variants like those associated with maturity onset diabetes in the young (MODY). Some individuals at increased risk won’t develop T2D, while some that do not have an increased risk will. Providers should consider personal and family history when assessing genetic testing needs. Genetic counseling or specialist consultation may aid further evaluation.
Get more information on how to order a MyOme test and get the process started.
Learn more about T2D iPRS
